Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1081-1100 of 2,120 trials

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Carpal Tunnel Syndrome: Injection vs. Surgery

We are comparing the effectiveness of ultrasound-guided injections to surgery for treating carpal tunnel syndrome. This study will help determine which approach may be better for patients in the long run.

Carpal Tunnel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases

We are studying a new treatment for people with active B-driven autoimmune diseases like lupus and scleroderma. The trial aims to evaluate its safety and initial effectiveness in managing these conditions.

Refractory Systemic Autoimmune Diseases3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Acute Pulmonary Embolism: Reduced Dose Thrombolytic Treatment

We are studying whether a lower dose of thrombolytic therapy is effective and safe for patients with intermediate high-risk acute pulmonary embolism. This research aims to improve treatment outcomes and reduce health risks.

Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyInternal MedicinePulmonology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyDermatology

Glycopyrronium for Asthma in Children

We are studying how well glycopyrronium works for children aged 6 to under 12 with asthma. The trial will also look at its safety and any side effects.

Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPediatricsPulmonology

NRAS Mutant Melanoma: Naporafenib + Trametinib Study

We are testing a new combination therapy for patients with previously treated NRAS mutant cutaneous melanoma. The goal is to see if it works better than standard treatment options in improving survival and managing the disease.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOncology